Using advanced analytics to assess an asset moving into PII in multiple indications

Using advanced analytics to assess an asset moving into PII in multiple indications

The Challenge

Provide in-depth disease understanding of a high specialized tumor type and clinical pathway. And ultimately, assess the commercial opportunity in multiple indications (1L or 2L, all-comer or targeted) amongst KOLs and wider prescribing community.

Our Approach

Using our Multi-indication Decision Analysis (MiDA) a systematic and standardized approach. It is designed to break down decision-making. It allowed multiple indications to be assessed in a single interview in US and EU. We conducted 75-minute tele-web  interviews that included a TPP co-creation exercise and patient flow pre-task

The Outcome

Through assessing the product through the lens of different indications we were able to provide a clear order of priority in terms of opportunity and adoption. The modelling exercise creates an indication score and ranking. The score, generated in real-time in the interview. MiDA scores are presented to physicians and evaluated. MiDA delivers clear evidence-based guidance related to unmet needs and relative opportunities. Co-creation optimized the subsequent TPP in the target indication. Recommendations were supported by in-depth disease understanding and existing treatment pathways and thorough assessment and mapping of the future landscape. Finally, we evaluated the asset’s potential uptake amongst the wider prescribing population.

Related case studies

Oncology future landscaping and positioning
Oncology future landscaping and positioning

View case study

MS treatment landscaping and decision-making
MS treatment landscaping and decision-making

View case study

Category navigation and path to purchase in consumer health
Category navigation and path to purchase in consumer health

View case study